HCA
CRNX icon

Harbour Capital Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Harbour Capital Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,550
Closed -$242K – 280
2024
Q4 		$242K Hold
4,550
– – 0.05% 257
2024
Q3 		$231K Hold
4,550
– – 0.05% 261
2024
Q2 		$210K Buy
+4,550
New +$210K 0.05% 265

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbour Capital Advisors's CRNX Position: Q1 2025 in Review

Harbour Capital Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 4,550 shares — an estimated $242K sold.

Harbour Capital Advisors first reported a position in CRNX in Q2 2024 and held it in 3 quarters. The position peaked at $242K in Q4 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Harbour Capital Advisors reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Harbour Capital Advisors sold 4,550 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $242K.
  • Harbour Capital Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Harbour Capital Advisors's Crinetics Pharmaceuticals position peaked at $242K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Harbour Capital Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.